Clinical Trial Update: Study of ET190L1 ARTEMIS™ T Cells in Relapsed and Refractory CD19+ Non-Hodgkin's Lymphoma [Phase 1]

View source ↗

Summary

The Phase 1 study of ET190L1 ARTEMIS T Cells in relapsed and refractory CD19+ non-Hodgkin lymphoma has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Lymphoma
• Non-hodgkin Lymphoma

Drugs mentioned

• ET190L1 ARTEMIS T Cells (ET190L1 ARTEMIS T cells)

Snippet

Sponsor: Eureka Therapeutics Inc. | Conditions: Lymphomas Non-Hodgkin's B-Cell | Phase 1 | Status: TERMINATED